{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:02:26Z","timestamp":1791226946767,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"KAKENHI program of the Japan Society for the Promotion of Science grant, Japan Agency for Medical Research and Development grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04242-6","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:21:46Z","timestamp":1766125306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Th7R predicts chemo-immunotherapy response and survival in small cell lung cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Shota","family":"Takei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shiono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"4242_CR1","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2025.0560","volume":"333","author":"SY Kim","year":"2025","unstructured":"Kim SY, Park HS, Chiang AC (2025) Small cell lung cancer: a review. JAMA 333:1906\u20131917. https:\/\/doi.org\/10.1001\/jama.2025.0560","journal-title":"JAMA"},{"key":"4242_CR2","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/s0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929\u20131939. https:\/\/doi.org\/10.1016\/s0140-6736(19)32222-6","journal-title":"Lancet"},{"key":"4242_CR3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"key":"4242_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares L, Chen Y, Reinmuth N et al (2022) Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 7:100408. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100408","journal-title":"ESMO Open"},{"key":"4242_CR5","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/jco.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G et al (2023) Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol 41:1992\u20131998. https:\/\/doi.org\/10.1200\/jco.22.01989","journal-title":"J Clin Oncol"},{"key":"4242_CR6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/jco.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A et al (2023) Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol 41:1999\u20132006. https:\/\/doi.org\/10.1200\/jco.22.01990","journal-title":"J Clin Oncol"},{"key":"4242_CR7","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko K, Matsumura N, Hamanishi J et al (2015) IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 112:1501\u20131509. https:\/\/doi.org\/10.1038\/bjc.2015.101","journal-title":"Br J Cancer"},{"key":"4242_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112393","author":"E Acheampong","year":"2020","unstructured":"Acheampong E, Abed A, Morici M, Bowyer S, Amanuel B, Lin W, Millward M, Gray ES (2020) Tumour PD-L1 expression in small-cell lung cancer: a systematic review and meta-analysis. Cells. https:\/\/doi.org\/10.3390\/cells9112393","journal-title":"Cells"},{"key":"4242_CR9","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1158\/2159-8290.Cd-20-0913","volume":"11","author":"NR Mahadevan","year":"2021","unstructured":"Mahadevan NR, Knelson EH, Wolff JO et al (2021) Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity. Cancer Discov 11:1952\u20131969. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0913","journal-title":"Cancer Discov"},{"key":"4242_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002891","author":"MV Negrao","year":"2021","unstructured":"Negrao MV, Skoulidis F, Montesion M et al (2021) Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002891","journal-title":"J Immunother Cancer"},{"key":"4242_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502099","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC et al (2025) Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2502099","journal-title":"N Engl J Med"},{"key":"4242_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"Kallies A, Zehn D, Utzschneider DT (2020) Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol 20:128\u2013136. https:\/\/doi.org\/10.1038\/s41577-019-0223-7","journal-title":"Nat Rev Immunol"},{"key":"4242_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","volume":"23","author":"T Gebhardt","year":"2023","unstructured":"Gebhardt T, Park SL, Parish IA (2023) Stem-like exhausted and memory CD8(+) T cells in cancer. Nat Rev Cancer 23:780\u2013798. https:\/\/doi.org\/10.1038\/s41568-023-00615-0","journal-title":"Nat Rev Cancer"},{"key":"4242_CR14","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen A, Hamon P, Fiaschi N et al (2023) Intratumoral dendritic cell-CD4(+) T helper cell niches enable CD8(+) T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med 29:1389\u20131399. https:\/\/doi.org\/10.1038\/s41591-023-02345-0","journal-title":"Nat Med"},{"issue":"1202\u201316","key":"4242_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.025","volume":"42","author":"G Espinosa-Carrasco","year":"2024","unstructured":"Espinosa-Carrasco G, Chiu E, Scrivo A et al (2024) Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42(1202\u201316):e8. https:\/\/doi.org\/10.1016\/j.ccell.2024.05.025","journal-title":"Cancer Cell"},{"issue":"318\u201334","key":"4242_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.01.002","volume":"40","author":"A Asrir","year":"2022","unstructured":"Asrir A, Tardiveau C, Coudert J et al (2022) Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell 40(318\u201334):e9. https:\/\/doi.org\/10.1016\/j.ccell.2022.01.002","journal-title":"Cancer Cell"},{"key":"4242_CR17","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/0008-5472.Can-22-0112","volume":"82","author":"H Kagamu","year":"2022","unstructured":"Kagamu H, Yamasaki S, Kitano S et al (2022) Single-cell analysis reveals a CD4+ T-cell cluster that correlates with PD-1 blockade efficacy. Cancer Res 82:4641\u20134653. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-0112","journal-title":"Cancer Res"},{"key":"4242_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1158\/2767-9764.Crc-23-0167","volume":"3","author":"A Yanagihara","year":"2023","unstructured":"Yanagihara A, Yamasaki S, Hashimoto K et al (2023) A Th1-like CD4(+) T-cell cluster that predicts disease-free survival in early-stage lung cancer. Cancer Res Commun 3:1277\u20131285. https:\/\/doi.org\/10.1158\/2767-9764.Crc-23-0167","journal-title":"Cancer Res Commun"},{"key":"4242_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/2326-6066.Cir-19-0574","volume":"8","author":"H Kagamu","year":"2020","unstructured":"Kagamu H, Kitano S, Yamaguchi O et al (2020) CD4(+) T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy. Cancer Immunol Res 8:334\u2013344. https:\/\/doi.org\/10.1158\/2326-6066.Cir-19-0574","journal-title":"Cancer Immunol Res"},{"key":"4242_CR20","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41590-020-0791-5","volume":"21","author":"G Galletti","year":"2020","unstructured":"Galletti G, De Simone G, Mazza EMC et al (2020) Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans. Nat Immunol 21:1552\u20131562. https:\/\/doi.org\/10.1038\/s41590-020-0791-5","journal-title":"Nat Immunol"},{"key":"4242_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH (2019) Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 19:307\u2013325. https:\/\/doi.org\/10.1038\/s41568-019-0144-6","journal-title":"Nat Rev Cancer"},{"key":"4242_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157215","author":"M Ukita","year":"2022","unstructured":"Ukita M, Hamanishi J, Yoshitomi H et al (2022) CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.157215","journal-title":"JCI Insight"},{"key":"4242_CR23","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","volume":"40","author":"Y Hua","year":"2022","unstructured":"Hua Y, Vella G, Rambow F et al (2022) Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1(+) T lymphocyte niches through a feed-forward loop. Cancer Cell 40:1600\u201318.e10. https:\/\/doi.org\/10.1016\/j.ccell.2022.11.002","journal-title":"Cancer Cell"},{"key":"4242_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221985120","volume":"120","author":"SJ Im","year":"2023","unstructured":"Im SJ, Obeng RC, Nasti TH et al (2023) Characteristics and anatomic location of PD-1(+)TCF1(+) stem-like CD8 T cells in chronic viral infection and cancer. Proc Natl Acad Sci U S A 120:e2221985120. https:\/\/doi.org\/10.1073\/pnas.2221985120","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4242_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","volume":"5","author":"MZ Jin","year":"2020","unstructured":"Jin MZ, Jin WL (2020) The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther 5:166. https:\/\/doi.org\/10.1038\/s41392-020-00280-x","journal-title":"Signal Transduct Target Ther"},{"key":"4242_CR26","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1186\/s12885-024-12843-0","volume":"24","author":"S Xu","year":"2024","unstructured":"Xu S, Zheng Y, Ye M, Shen T, Zhang D, Li Z, Lu Z (2024) Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response. BMC Cancer 24:1064. https:\/\/doi.org\/10.1186\/s12885-024-12843-0","journal-title":"BMC Cancer"},{"key":"4242_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer MH, Carmi Y, Reticker-Flynn NE et al (2017) Systemic immunity is required for effective cancer immunotherapy. Cell 168:487-502.e15. https:\/\/doi.org\/10.1016\/j.cell.2016.12.022","journal-title":"Cell"},{"key":"4242_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM et al (2021) Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39:346\u201360.e7. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.014","journal-title":"Cancer Cell"},{"key":"4242_CR29","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jtho.2019.03.028","volume":"14","author":"P Muppa","year":"2019","unstructured":"Muppa P, Parrilha Terra SBS, Sharma A et al (2019) Immune cell infiltration may be a key determinant of long-term survival in small cell lung cancer. J Thorac Oncol 14:1286\u20131295. https:\/\/doi.org\/10.1016\/j.jtho.2019.03.028","journal-title":"J Thorac Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04242-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:01:51Z","timestamp":1766170911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04242-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4242"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04242-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OY reports personal fees from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Nippon Kayaku, Daiichi Sankyo, MSD, Novartis Pharma K.K., Kyowa Kirin Co., Ltd., Amgen K.K., and Janssen Pharmaceutical K.K. KK reports personal fees from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and AstraZeneca and research grants from AstraZeneca. HK reports personal fees from Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, Chugai Pharmaceutical Co., AstraZeneca, MSD, and research grants from Boehringer Ingelheim, Chugai Pharmaceutical Co., Nippon Kayaku. No disclosures were reported by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Institutional Review Board of Saitama Medical University International Medical Center in accordance with the Declaration of Helsinki (approval number: 16\u2013281).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"17"}}